6533b86ffe1ef96bd12cdc06
RESEARCH PRODUCT
Lack of association betweenMDM2promoter SNP309 and clinical outcome in patients with neuroblastoma
Johannes H. SchulteBram De WildeSimona CocoRaymond L. StallingsRaymond L. StallingsFjoralba ZekaAngelika EggertAli RihaniJo VandesompeleTom Van MaerkenRosa NogueraFranki SpelemanGenevieve LaureysRogier VersteegKoen NorgaGian Paolo Toninisubject
biologybusiness.industryMdm2 snp309PromoterSingle-nucleotide polymorphismHematologymedicine.diseaseenzymes and coenzymes (carbohydrates)OncologyNeuroblastomaPediatrics Perinatology and Child HealthGenotypebiology.proteinCancer researchMedicineMdm2In patientbusinessneoplasmsGenotypingdescription
While a polymorphism located within the promoter region of the MDM2 proto-oncogene, SNP309 (T > G), has previously been associated with increased risk and aggressiveness of neuroblastoma and other tumor entities, a protective effect has also been reported in certain other cancers. In this study, we evaluated the association of MDM2 SNP309 with outcome in 496 patients with neuroblastoma and its effect on MDM2 expression. No significant difference in overall or event-free survival was observed among patients with neuroblastoma with or without MDM2 SNP309. The presence of SNP309 does not affect MDM2 expression in neuroblastoma. Pediatr Blood Cancer 2014; 61:1867–1870. © 2014 Wiley Periodicals, Inc.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-01-04 | Pediatric Blood & Cancer |